Arsenic trioxide added to chemotherapy for children whose medulloblastoma came back
Original title: Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study in people, and the results are not in yet.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called arsenic trioxide, added to chemotherapy, in children whose brain tumor came back.
Who this trial is for. This trial is for children 18 months to 18 years old. Their medulloblastoma came back or did not respond to treatment. The tumors have SHH-activated and/or TP53-mutant changes. Children would get six cycles of chemotherapy with arsenic trioxide added.
Where it stands. This trial has not reported results. The main thing being measured is how many tumors shrink. The team will also track how long children live, how long tumors stay in check, and side effects. The study plans to include 78 children. The answers are not in yet.
What this means, and what it doesn't
What it could mean: A family whose child fits this picture may want to ask their care team about it. The child's doctors can say whether this kind of study makes sense for them.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a promise of benefit. This is not a cure.
Source: ClinicalTrials.gov, October 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.